

COMPANY ANNOUNCEMENT

5 February 2026

Santander International Products plc
(the “**Issuer**”)

Issue of up to EUR 3,000,000 “Mediolanum MedPlus Certificate Express S432” due February 2032 (ISIN: IT0006773201) (the “**Notes**”)

Guaranteed by

BANCO SANTANDER, S.A.

under the

EUR 15,000,000,000 Euro Medium Term Note Programme

(the “**Programme**”)

RE: Article 17 Announcement – Series 5351

In relation to the issue of the Notes on 6 February 2026, issued pursuant to the Base Prospectus dated 1 July 2025, and the Final Terms dated 19 January 2026, which constitute a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, the Issuer gives notice of the following information:

The aggregate principal amount of the Notes is EUR 2,250,000.

This notice will be filed with the Central Bank of Ireland.

Signed on behalf of the Issuer

By:



Duly authorised

By:



Duly authorised